Who Should NOT Take GLP-1 for Weight Loss?
GLP-1 medications like Mounjaro (tirzepatide) are transforming weight loss – but are they safe for everyone? Over the past few years, GLP-1 receptor agonists have moved from diabetes treatment rooms to mainstream weight management conversations, and for good reason. Clinical trials show that tirzepatide can help patients lose up to 20-22% of their body weight (New England Journal of Medicine, 2022). In India, where the National Family Health Survey-5 (2019-21) reports that 24% of women and 23% of men are overweight or obese, the demand for effective weight-loss solutions has never been greater.
But here’s the truth most online promotions won’t tell you: GLP-1 medications are not right for everyone. At Gutwell, Gurgaon’s leading weight loss clinic, we believe safe treatment always comes before a quick fix. Dr. Surkti Singh Sethi and our medical team conduct thorough evaluations before recommending any GLP-1 therapy, including Mounjaro(tirzepatide) & Wegovy (semaglutide in Gurgaon.
What Are GLP-1 Medications?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of prescription-only medications that mimic a natural gut hormone. They work by slowing digestion, reducing appetite, and improving blood sugar regulation. Well-known examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), the latter also targeting GIP receptors for enhanced effect. These are not over-the-counter supplements – they require a doctor’s prescription and ongoing medical supervision.
Who Should NOT Take GLP-1?
Absolute Contraindications
The following groups should NOT use GLP-1 medications under any circumstances:
- Personal or family history of medullary thyroid carcinoma (MTC) : GLP-1 drugs carry an FDA Black Box Warning for thyroid C-cell tumours.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) : a rare hereditary condition that significantly raises thyroid cancer risk.
- Pregnancy or actively trying to conceive : these medications are not studied in pregnant women and must be discontinued at least 2 months before conception.
- Known severe allergic reaction (anaphylaxis) to any GLP-1 drug or its ingredients.
People Who Need Careful Medical Supervision
Not everyone in this group is automatically disqualified – but they require a thorough expert evaluation before starting any GLP-1 medication:
- History of acute or chronic pancreatitis : GLP-1 drugs have been associated with pancreatic inflammation in some cases.
- Severe gastroparesis (delayed stomach emptying) : since GLP-1 further slows gastric motility, this can worsen symptoms significantly.
- Significant kidney disease : dehydration risk from nausea/vomiting can accelerate kidney damage.
- Active liver disease or gallbladder problems : GLP-1 use has been linked to gallstone formation in some patients.
- Elderly patients (65+ years) or those on multiple medications : risk of drug interactions and muscle mass loss requires careful management.
- Type 1 diabetes : GLP-1 medications are not a substitute for insulin therapy.
Source: U.S. FDA prescribing information for tirzepatide (Mounjaro); Central Drugs Standard Control Organisation (CDSCO) India advisory on GLP-1 receptor agonists.
Who Might NOT Benefit Much from GLP-1 Therapy?
Even if you are medically eligible, GLP-1 therapy may not deliver the results you hope for in certain situations. Research published in the journal Obesity (2023) confirms that approximately 10-15% of patients are ‘non-responders’ – individuals who show minimal weight loss despite correct dosing.
- People expecting a quick fix without lifestyle change : GLP-1 medications work best alongside dietary changes and regular physical activity.
- Those unwilling or unable to commit to regular follow-up appointments and monitoring.
- Individuals with a BMI under 27 kg/m² without weight-related health conditions, as clinical benefits in this group are less established.
Read also : Doctor-Supervised GLP-1 Weight Loss Program in Gurgaon
Why Medical Screening Is Non-Negotiable
The rise of online pharmacies and social media has made GLP-1 medications dangerously easy to access without proper evaluation. Self-medicating with prescription weight-loss drugs like Mounjaro or semaglutide can lead to serious complications, including severe nausea, pancreatitis, dangerous blood sugar swings, and cardiovascular stress.
At Gutwell, every GLP-1 treatment plan begins with:
- A complete medical history review, including family history of thyroid or endocrine cancers.
- Baseline lab investigations: HbA1c, thyroid function, liver enzymes, kidney function, and lipid profile.
- Body composition assessment : not just weight, but muscle vs. fat ratio.
- Monthly monitoring appointments to track progress and adjust dosing safely.
Data from India’s ICMR-INDIAB study (2023) highlights that metabolic disorders including diabetes, hypertension, and dyslipidemia frequently co-exist in obese Indian adults – making comprehensive screening even more critical before initiating any pharmacological weight loss treatment.
Expert Perspective: Dr. Surkti Singh Sehti, Gutwell
GP-1 medications represent a genuine medical breakthrough in obesity management – but breakthrough tools still require expert hands. At Gutwell, I see patients every week who have tried self-prescribed weight loss medications based on social media trends, often with harmful outcomes. My approach is always patient-first: we don’t just look at your weight, we look at your whole health picture. For patients who are right candidates, Mounjaro can be life-changing. For those who are not, there are equally effective, safer alternatives. The goal is always long-term, sustainable weight management — not a number on a scale next month.”
– Dr. Surkti Singh Sehti, Weight Loss Expert, Gutwell Clinic, Gurgaon
The Bottom Line
GLP-1 medications like Mounjaro are among the most powerful weight loss tools available today – but they are prescription medications with real contraindications, real side effects, and real requirements for medical oversight. They are not for everyone, and that’s okay. Understanding who should not take GLP-1 is just as important as knowing who benefits most.
If you are considering GLP-1 or Mounjaro in Gurgaon, do not self-prescribe. A brief consultation can protect your health and ensure you are on the path that is right for you – not just trending on the internet.
Book Your Consultation at Gutwell, Gurgaon
Consult Dr. Surkti Singh Sehti for a safe, personalised GLP-1 assessment. Whether you’re exploring Mounjaro or other weight loss treatment options in Gurgaon, our team provides evidence-based care tailored to your unique health profile.
➡️ [Book a Consultation] – [Learn About GLP-1 Treatment at Gutwell] – [Mounjaro in Gurgaon]
Frequently Asked Questions
Q1: Can I take GLP-1 if I have thyroid disease?
It depends on the type. If you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome, GLP-1 medications including Mounjaro are contraindicated. For other thyroid conditions like hypothyroidism, suitability must be assessed individually by a doctor.
Q2: Are GLP-1 medications safe for people with kidney disease?
Mild-to-moderate kidney disease may not automatically disqualify you, but severe kidney impairment is a significant risk factor. GLP-1 medications can cause dehydration through nausea and vomiting, which places extra stress on the kidneys. A nephrologist’s clearance is advisable before starting treatment.
Q3: Is Mounjaro available in Gurgaon, and who can prescribe it?
Yes, Mounjaro (tirzepatide) is available in Gurgaon through licensed medical practitioners. It is a prescription medication and cannot be legally or safely obtained without one. At Gutwell Clinic in Gurgaon, Dr. Surkti Singh Sehti offers medically supervised Mounjaro weight loss programs with full pre-treatment screening and ongoing monitoring.
Sources & References
- National Family Health Survey-5 (NFHS-5), 2019–21 — Ministry of Health & Family Welfare, Government of India. rchiips.org/nfhs
- ICMR-INDIAB Study 2023 — Indian Council of Medical Research. icmr.gov.in
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. doi:10.1056/NEJMoa2206038
- U.S. FDA Prescribing Information — Mounjaro (tirzepatide). fda.gov
- Central Drugs Standard Control Organisation (CDSCO) — GLP-1 Agonist Regulatory Status in India. cdsco.gov.in
Medical Disclaimer: This blog is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new medication or weight loss program. GLP-1 medications are prescription drugs; individual suitability varies.
